Wisconsin Legislature: CSB 2.009 Note

CSB 2.009 History History: cr. Affirmative action order under s. 961.11 (4), Stats., Register July 2021 No. 787, eff. 7-19-21; correction made under s. 35.17, Stats., Register July 2021 No. 787; CR 22-035: cr. Register June 2023 No. 810, eff. 7-1-23.

CSB 2.009 Note CSB 2.86 Addition of fospropofol to schedule IV. Section 961.20 (2) (en), Stats., is created to read:

CSB 2.009 Note 961.20 (2) (en) Fospropofol;

CSB 2.009 Note CSB 2.87 Addition of embutramide to schedule III. Section 961.18 (3) (bm), Stats., is created to read:

CSB 2.009 Note 961.18 (3) (bm) Embutramide;

CSB 2.009 Note CSB 2.88 Addition of lacosamide to schedule V. Section 961.22 (10), Stats., is created to read:

CSB 2.009 Note 961.22 (10) Lacosamide.

CSB 2.009 History History: cr. Affirmative action order under s. 961.11 (4), Stats., Register July 2021 No. 787, eff. 7-19-21; CR 22-039: cr. Register June 2023 No. 810, eff. 7-1-23.

CSB 2.009 Note CSB 2.89 Addition of perampanel to schedule III. Section 961.18 (3) (fm), Stats., is created to read:

CSB 2.009 Note 961.18 (3) (fm) Perampanel.

CSB 2.009 Note CSB 2.90 Transfer of 1-phenylcyclohexylamine and 1-piperidinocyclohexanecarbonitrile, immediate precursors to phencyclidine, also known as PCP, from schedule I to schedule II. Section 961.16 (8) (c), Stats., is created to read:

CSB 2.009 Note 961.16 (8) (c) Immediate precursors to phencyclidine, also known as PCP:

CSB 2.009 Note 1. 1-phenylcyclohexylamine.

CSB 2.009 Note 2. 1-piperidinocyclohexanecarbonitrile.

CSB 2.009 Note CSB 2.91 Addition of 4,4'-Dimethylaminorex to schedule I. Section 961.14 (7) (cm), Stats., is created to read:

CSB 2.009 Note 961.14 (7) (cm) 4,4'-Dimethylaminorex.

CSB 2.009 History History: cr. Affirmative action order under s. 961.11 (4), Stats., Register September 2021 No. 789, eff. 9-27-21; CR 22-054: cr. Register June 2023 No. 810, eff. 7-1-23.

CSB 2.009 Note CSB 2.92 Addition of thirty-five (35) Anabolic Steroids to schedule III. Section 961.18 (7), Stats., is repealed and recreated to read:

CSB 2.009 Note 961.18 (7) ANABOLIC STEROIDS. Unless specifically excepted or listed in another schedule, any material, compound, mixture, or preparation containing any quantity of any of the following anabolic steroids, including any of their esters, ethers, isomers, esters or ethers of isomers, salts and salts of esters or ethers, isomers and esters or ethers of isomers that are theoretically possible within the specific chemical designation. Except such terms do not include an anabolic steroid that is expressly intended for administration through implants to cattle or other nonhuman species and that has been approved by the Secretary of Health and Human Services for such administration. If any person prescribes, dispenses, or distributes such steroid for human use, the person shall be considered to have prescribed, dispensed, or distributed an anabolic steroid within the meaning of this section:

CSB 2.009 Note (a) 3beta,17-dihydroxy-5alpha-androstane.

CSB 2.009 Note (ag) 3alpha,17beta-dihydroxy-5alpha-androstane.

CSB 2.009 Note (ar) 5alpha-androstan-3,17-dione.

CSB 2.009 Note (b) 1-androstenediol (3beta,17beta-dihydroxy-5alpha-androst-1-ene; 3alpha,17beta-dihydroxy-5alpha-androst-1-ene).

CSB 2.009 Note (bg) 4-androstenediol.

CSB 2.009 Note (br) 5-androstenediol.

CSB 2.009 Note (c) 1-androstenedione.

CSB 2.009 Note (cg) 4-androstenedione.

CSB 2.009 Note (cr) 5-androstenedione.

CSB 2.009 Note (d) Bolasterone.

CSB 2.009 Note (dg) Boldenone.

CSB 2.009 Note (dr) Boldione.

CSB 2.009 Note (e) Calusterone.

CSB 2.009 Note (eg) 4-chlorotestosterone, which is also called clostebol.

CSB 2.009 Note (er) Dehydrochloromethyltestosterone.

CSB 2.009 Note (f) Desoxymethyltestosterone.

CSB 2.009 Note (fg) Delta1-dihydrotestosterone.

CSB 2.009 Note (fr) 4-dihydrotestosterone, which is also called stanolone.

CSB 2.009 Note (g) Drostanolone.

CSB 2.009 Note (gg) Ethylestrenol.

CSB 2.009 Note (gr) Fluoxymesterone.

CSB 2.009 Note (h) Formebulone, which is also called fromebolone.

CSB 2.009 Note (hg) Furazabol.

CSB 2.009 Note (hr) 13beta-ethyl-17beta-hydroxygon-4-en-3-one.

CSB 2.009 Note (i) 4-hydroxytestosterone.

CSB 2.009 Note (ig) 4-hydroxy-19-nortestosterone.

CSB 2.009 Note (ir) Mestanolone.

CSB 2.009 Note (j) Mesterolone.

CSB 2.009 Note (jg) Methandienone, which is also called methandrostenolone.

CSB 2.009 Note (jr) Methandriol.

CSB 2.009 Note (k) Methasterone.

CSB 2.009 Note (kg) Methenolone.

CSB 2.009 Note (kr) 17alpha-methyl-3beta, 17beta-dihydroxy-5alpha-androstane.

CSB 2.009 Note (L) 17alpha-methyl-3alpha,17beta-dihydroxy-5alpha-androstane.

CSB 2.009 Note (Lg) 17alpha-methyl-3beta,17beta-dihydroxyandrost-4-ene.

CSB 2.009 Note (Lr) 17alpha-methyl-4-hydroxynandrolone.

CSB 2.009 Note (m) Methyldienolone.

CSB 2.009 Note (mg) Methyltestosterone.

CSB 2.009 Note (mr) Methyltrienolone.

CSB 2.009 Note (n) Mibolerone.

CSB 2.009 Note (ng) 17alpha-methyl-delta1-dihydrotestosterone, which is also called 17-alpha-methyl-1-testosterone.

CSB 2.009 Note (nr) Nandrolone.

CSB 2.009 Note (o) 19-nor-4-androstenediol (3beta, 17beta-dihydroxyestr-4-ene; 3alpha, 17beta-dihydroxyestr-4-ene).

CSB 2.009 Note (og) 19-nor-5-androstenediol (3beta, 17beta-dihydroxyestr-5-ene; 3alpha, 17beta-dihydroxyestr-5-ene).

CSB 2.009 Note (or) 19-nor-4,9(10)-androstadienedione.

CSB 2.009 Note (p) 19-nor-4-androstenedione (estr-4-en-3,17-dione).

CSB 2.009 Note (pg) 19-nor-5-androstenedione (estr-5-en-3,17-dione).

CSB 2.009 Note (pr) Norbolethone.

CSB 2.009 Note (q) Norclostebol.

CSB 2.009 Note (qg) Norethandrolone.

CSB 2.009 Note (qr) Normethandrolone.

CSB 2.009 Note (r) Oxandrolone.

CSB 2.009 Note (rg) Oxymesterone.

CSB 2.009 Note (rr) Oxymetholone.

CSB 2.009 Note (s) Prostanozol.

CSB 2.009 Note (sg) Stanozolol.

CSB 2.009 Note (sr) Stenbolone.

CSB 2.009 Note (t) Testolactone.

CSB 2.009 Note (tg) Testosterone.

CSB 2.009 Note (tr) Tetrahydrogestrinone.

CSB 2.009 Note (u) Trenbolone.

CSB 2.009 History History: cr. Affirmative action order under s. 961.11 (4), Stats., Register August 2022 No. 800, eff. 7-25-22; correction made under s. 35.17, Stats., Register August 2022 No. 800; CR 23-018: cr. Register April 2024 No. 820, eff. 5-1-24.

CSB 2.009 Note CSB 2.93 Addition of Daridorexant to schedule IV. Section 961.20 (2) (cpm), Stats., is created to read:

CSB 2.009 Note 961.20 (2) (cpm) Daridorexant;

CSB 2.009 Note CSB 2.94 Addition of seven (7) synthetic benzimidazole-opioid substances to schedule I. (1) Section 961.14 (2) (mm) and (pe), Stats., are renumbered to 961.14 (2) (xm) 3. and 5. and amended to read: